Zydus Lifesciences Limited launched the molecule Sitagliptin in India under the brand names Sitaglyn ® and Siglyn® to address Type 2 diabetes in India. Sitaglyn® and Siglyn® will add on to a comprehensive solution for the
management of Type 2 diabetes by providing access to quality care to the patients at an affordable cost, approximately 60% lesser than the originator. Sitaglyn® and Siglyn® offer an oral solution to the patients providing ease of convenience and better compliance. Sitagliptin is the gold standard in the Dipeptidyl peptidase 4 inhibitor (DPP4i) category with over 62% market share in the global market. The drug provides best in class achievement of Hemoglobin A1C (HbA1c) goals with proven safety profile. With more than 77 million active patients, India is the diabetes capital of the world after China. As per the data, 67% of these patients are unable to achieve their HbA1c goal.